This Biotech Stock Is Up 291% From Its IPO Price. It’s On Pace for a Record Closing High.
CG Oncology stock is on pace for a record closing high after ‘best case’ Phase 3 trial results for its bladder cancer treatment.
CG Oncology stock is on pace for a record closing high after ‘best case’ Phase 3 trial results for its bladder cancer treatment.